Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Innate immune detection of lipid oxidation as a threat assessment strategy

Abstract

Oxidized phospholipids that result from tissue injury operate as immunomodulatory signals that, depending on the context, lead to proinflammatory or anti-inflammatory responses. In this Perspective, we posit that cells of the innate immune system use the presence of oxidized lipids as a generic indicator of threat to the host. Similarly to how pathogen-associated molecular patterns represent general indicators of microbial encounters, oxidized lipids may be the most common molecular feature of an injured tissue. Therefore, microbial detection in the absence of oxidized lipids may indicate encounters with avirulent microorganisms. By contrast, microbial detection and detection of oxidized lipids would indicate encounters with replicating microorganisms, thereby inducing a heightened inflammatory and defensive response. Here we review recent studies supporting this idea. We focus on the biology of oxidized phosphocholines, which have emerged as context-dependent regulators of immunity. We highlight emerging functions of oxidized phosphocholines in dendritic cells and macrophages that drive unique inflammasome and migratory activities and hypermetabolic states. We describe how these lipids hyperactivate dendritic cells to stimulate antitumour CD8+ T cell immunity and discuss the potential implications of the newly described activities of oxidized phosphocholines in host defence.

Introduction

The innate and adaptive arms of immunity operate as generalists and specialists, respectively. General molecular patterns that are associated with microbial life are used by pattern recognition receptors (PRRs) to detect potential infections1,2 (Box 1). The microbial molecules are referred to as pathogen-associated molecular patterns (PAMPs). However, the specific identity of the potential pathogen is not identified by PRRs1. This specificity is provided by lymphocytes that bear antigen receptors, which are precise in their identification of individual pathogens. The link between generalists (PRRs) and specialists (antigen receptors) is causal, as genetic evidence indicates that PRR signalling on dendritic cells (DCs) is critical to stimulate antigen-specific responses by T cells3,4,5,6.

While PRRs are not designed to identify specific microorganisms, increasing evidence indicates that innate immune networks operate as threat-assessment stations, which can distinguish between microbial and pathogenic encounters7. The most commonly discussed means of distinguishing microorganisms from pathogens is through the coincident detection of PAMPs and virulence factor activities by distinct innate immune receptors8,9. Microorganisms contain PAMPs but have no virulence factors, whereas pathogens contain both9. An example of threat assessment involves the induction of pyroptosis, an inflammatory form of cell death that can be triggered upon coincident detection of PAMPs and virulence factor activities10,11,12,13. One of the challenges of this strategy of threat assessment is the unique repertoire of virulence factors encoded by individual pathogens. A general means of identifying threats to the host, regardless of the virulence factor repertoire, may be useful and more symmetrical to the PAMP-based strategy of microbial detection used by PRRs.

Herein we discuss data suggesting a distinct strategy of threat assessment by the innate immune system, which is not mediated by specific virulence factors. This process is rather mediated by one of the most common consequences of pathogen replication — oxidation of phospholipids in the environment following tissue injury. We discuss how oxidized phospholipids (oxPLs) operate as immunomodulatory signals that may provide a generic indication of the context of PAMP detection to the host. PAMP detection in the absence of oxPLs may represent contexts where non-replicating microorganisms have been encountered (that is, low threat encounters). By contrast, PAMP detection in the presence of oxidized products may represent contexts of high threat, where replicating microorganisms (that is, pathogens) have been encountered. The benefit of such a strategy is that tissue injury-induced oxidation may be considered a common (and perhaps unavoidable) outcome of pathogen replication, regardless of the virulence factor repertoire. Thus, akin to the generic use of PAMPs as an indicator of microorganisms, the innate immune system may use PAMPs plus oxPLs as generic indicators of heightened threat. The mechanisms and consequences of oxPL detection by the innate immune system are discussed herein.

Phospholipid oxidation and recognition

Phospholipids such as phosphocholines are major constituents of mammalian cells. Under conditions of non-inflammatory or inflammatory tissue injury, any cell death that occurs in the local environment will result in the generation of reactive oxygen species (ROS). The source of the ROS may result from the actions of infiltrating neutrophils, dying mitochondria or the air itself. Under any of these conditions, phosphocholines in the plasma membrane can be oxidized. Defined examples of oxPL generation include tissue injury, lung infection in which an initial encounter with a pathogen is followed by tissue damage14, and during chronic inflammatory diseases such as atherosclerosis15. Mechanisms of oxPL generation are summarized in Box 2. In recent years, much focus has been on the arachidonic acid-containing phospholipid 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PAPC), which is a constituent of membranes in mammalian cells. Unlike their non-oxidized counterparts, oxPLs serve as damage-associated molecular patterns (DAMPs) and can modulate inflammation. Upon exposure to ROS, PAPC is oxidized at various positions to create a heterogeneous mixture of lipids collectively referred to as oxPAPCs. oxPAPCs are composed of a mixture of full-chain and truncated oxidized phosphocholine derivatives, which can be detected on dying cells and approach millimolar concentration in damaged tissues16. Growing interest has been focused on two components of oxPAPC — namely, 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC) and 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC)17. As opposed to PAMPs, which are intrinsically inflammatory, it is impossible to describe oxPAPCs as inducers or inhibitors of inflammation in all contexts. Rather, oxPAPCs display context-dependent activities, which is likely to be an important aspect of threat assessment.

Several oxPAPC receptors have been defined, each of which may impact oxPAPC-mediated inflammatory activity in different ways. On macrophages, the scavenger receptor CD36 binds oxPAPCs and induces their uptake. This process promotes foam cell formation during atherosclerosis18. The structural basis of oxPAPC binding to CD36 has been defined, with Lys164 and Lys166 being required for the binding with sn-2 acyl chains of oxPAPC19. oxPAPC binding to CD36 is blocked by E06, a monoclonal IgM antibody that recognizes the phosphocholine headgroup of oxPAPC (see Box 3), demonstrating the importance of the oxPAPC headgroup in binding to CD36 (ref.20).

In addition to CD36, oxPAPCs bind the bacterial lipopolysaccharide (LPS) receptor CD14 on myeloid cells, thereby allowing oxPAPC internalization into endosomes and transport to the cell cytosol21. In the context of oxPAPC-induced inflammatory activities (described in detail later), CD14 serves as the primary receptor for these oxPLs21. CD14 functions as a transporter associated with the execution of inflammation (TAXI) protein22, which delivers LPS from the bacterial cell wall to membrane-associated MD2 and Toll-like receptor 4 (TLR4). CD14 then transports LPS and TLR4 to signalling-competent subcellular regions22. Similarly to LPS, the interaction between oxPAPCs and CD14 results in CD14 endocytosis and depletion of CD14 from the plasma membrane21. Therefore, oxPAPCs compete with LPS for CD14 binding in cell-free experimental systems, an activity that likely explains why the pretreatment of naive cells with oxPAPCs blocks subsequent responses to LPS via TLR4 (ref.23).

Upon CD14-dependent endocytosis in macrophages and DCs, oxPAPCs gain access to the cytosol, where they bind the inflammasome regulators caspase 1 and caspase 11 (ref.24). oxPAPC–caspase interactions are thought to stimulate NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome assembly in a potassium-independent manner24. Like CD14, caspase 11 interacts with oxPAPCs and LPS. In vitro studies demonstrated that LPS interacts with the caspase activation and recruitment domain (CARD) of caspase 11, whereas oxPAPCs bind the catalytic domain of caspase 11 (ref.24). As a consequence, the functional impacts of oxPAPCs and LPS on caspase 11 are distinct. When LPS binds to caspase 11 in macrophages or DCs, this interaction induces inflammasome-dependent IL-1β release from macrophages, which is associated with pyroptosis. By contrast, oxPAPC binding to caspase 11 induces the release of IL-1β from living DCs, in the absence of pyroptosis24. The ability of oxPAPCs to bind the catalytic domain of caspase 11 was not associated with stimulation of its enzymatic activity, as is typically observed when inflammatory LPS structures interact with the caspase 11 CARD25,26. Rather, oxPAPCs prevent intrinsic and LPS-induced caspase 11 activity24. This finding, coupled with the aforementioned competition between oxPAPCs and LPS for CD14, may explain why LPS-induced inflammation can be prevented by pretreatment of cells or mice with oxPAPCs. Many questions remain unanswered with regard to the biochemical interaction of oxPAPCs with CD14 and inflammatory caspases. In addition, how CD14 delivers oxPAPCs to the cytosol remains ambiguous, but it is possible that oxPAPCs alter the endosomal membrane and provoke their own leakage into the cytosol27.

In summary, oxPAPCs are recognized by multiple receptors on myeloid cells, which may lead to the crosstalk of diverse signalling pathways and the modulation of myeloid cell functions that we further describe in the following sections.

Consequences of oxPAPC recognition

The detection of oxPAPCs by macrophages or DCs can impact inflammatory activities in a diverse range of diseases, including acute inflammation, atherosclerosis, cancer, lung injury and age-related diseases16,28,29. Depending on the context in which oxPAPCs are encountered, these lipids exert proinflammatory or anti-inflammatory effects30. For example, during conditions representative of sterile tissue injury, oxPAPCs exert anti-inflammatory functions, perhaps by preventing efficient detection of other molecules that stimulate CD14, TLR4 or caspase 11. By contrast, at the site of infection where tissue damage is common, oxPAPCs exhibit proinflammatory activities in cells that have also detected PAMPs. In the following subsections we describe how oxPAPCs regulate innate immune functions of myeloid cells and influence the induction of adaptive immunity.

Impact of oxPAPCs on phagocytosis and endocytosis

Accumulating evidence demonstrates that oxPAPCs modulate phagocytosis by antigen-presenting cells in a cell type-specific and context-specific manner. For example, oxPAPC pretreatment of peritoneal macrophages diminished their ability to internalize Escherichia coli. In mice, pre-exposure to oxPAPCs led to a reduction in host defence, resulting in bacterial outgrowth and systemic dissemination31. Similarly, intratracheal instillation of an oxPAPC mixture or pure phosphocholine moieties (for example, POVPC or PGPC) rendered mice unable to eradicate subsequent infections with Pseudomonas aeruginosa32. oxPAPCs generated in the bronchoalveolar space of mice exposed to cigarette smoke impaired phagocytosis by alveolar macrophages32. The link between these in vivo defects in phagocytosis after oxPAPC exposure was established by means of the monoclonal antibody E06, which binds to and prevents the activities of several oxPAPC component lipids. E06 treatment prevented the inhibition of bacterial phagocytosis and restored bacterial clearance32.

In contrast to the bacterial exposures described above, oxPLs can stimulate phagocytosis of apoptotic cells by macrophages via CD36 (ref.33). In the context of non-phagocytic cargo, oxPAPCs did not affect dextran or soluble ovalbumin uptake by endocytosis. Moreover, in the presence of oxPAPCs, the ability of LPS-primed DCs to cross-present peptides on MHC class I molecules was enhanced34. These data are in accordance with reports indicating that within DCs, antigen leakage from endosomes for cross-presentation may occur upon direct oxidation of endosomal lipids and generation of oxPLs27. Thus, depending on the cargo to be internalized, oxPAPCs exhibit contrasting effects on phagocytic and endocytic activities. The molecular basis for these context-dependent behaviours is undefined.

Impact of oxPAPCs on inflammasome activities

Following priming with various TLR ligands, oxPAPCs induce a long-lived state of hyperactivation in myeloid cells24. This activation state is distinct from naive, active or pyroptotic cell states. A description of these cell states is provided in Box 4 and Fig. 1. A hallmark of oxPAPC-stimulated hyperactive cells is their ability to secrete inflammasome-dependent IL-1β while remaining viable. Extracellular oxPAPC components are detected by CD14 (ref.21). CD14-dependent endocytosis delivers these lipids to intracellular caspase 11. oxPAPC binding with caspase 11 leads to NLRP3-dependent inflammasome assembly and IL-1β release in the absence of cell death24. In contrast to the rapid but transient burst of IL-1β release that occurs upon exposure of phagocytes to pyroptotic stimuli, oxPAPCs or PGPC promote IL-1β release from LPS-primed cells for several days21.

Fig. 1: The T cell stimulatory activities of dendritic cells at distinct activation states.
figure 1

To regulate T cell activity, dendritic cells (DCs) provide T cells with several signals that are important for the establishment of an appropriate T cell response. Naive DCs are quiescent DCs that have the ability to take up antigens. Active DCs take up antigens and have an enhanced ability to present antigen peptides on MHC molecules. In addition, active DCs upregulate co-stimulatory molecules to stimulate T cells. Hyperactive DCs share similar activities with their active counterparts, but also gain the ability to hypermigrate to lymph nodes and to secrete IL-1β. Pyroptotic DCs secrete high levels of IL-1β. However, pyroptotic DCs are dead and lose their T cell stimulatory capacity.

IL-1β is a highly inflammatory cytokine and its secretion is tightly regulated35. TLR signalling induces production of pro-IL-1β, but this pro-protein form lacks an amino-terminal secretion signal and cannot be secreted via the endoplasmic reticulum–Golgi network35. To gain inflammatory activities, pro-IL-1β must be cleaved, most commonly by inflammatory caspases present within inflammasomes36. Inflammasomes are supramolecular organizing centres, which assemble in the cytoplasm following their activation36. Caspases that are activated within inflammasomes (most commonly caspase 1) cleave pro-IL-1β and gasdermin D (GSDMD). GSDMD cleavage unleashes the latent ability of its amino terminus to form pores in the plasma membrane. Pore formation is facilitated by interactions between GSDMD and acidic phosphoinositides present in the inner leaflet of the plasma membrane, such as phosphatidylinositol 4,5-bisphosphate and phosphatidylserine37. GSDMD pores serve as conduits for mature IL-1β secretion in a cell lysis-independent event38,39. Cargo transport across the negatively charged GSDMD conduit occurs via a size-exclusion mechanism38,39, as well as by electrostatic filtering of cytosolic proteins, which favours the release of the positively charged mature IL-1β, while repelling pro-IL-1β40. If GSDMD pores are not repaired by the cell, pyroptotic cell death may occur, during which IL-1β and other cytosolic contents can be released non-selectively. Of the well-defined inflammasome agonists, including intracellular LPS, ATP, nigericin and alum, all induce pyroptosis. By contrast, within TLR ligand-stimulated cells, oxPAPCs induce inflammasome-dependent release of IL-1β through GSDMD pores in the absence of cell death. The ability of oxPAPCs to add IL-1β to the repertoire of factors that are normally secreted by living phagocytes renders these cells more immunostimulatory than their activated counterparts that have been stimulated only with PAMPs — hence the term ‘hyperactive’. Hyperactive cells display evidence of fewer GSDMD pores at their surface than their pyroptotic counterparts39. Whether GSDMD pores in hyperactive cells are regulated similarly as in pyroptotic cells downstream of inflammasome activation is unknown. Hyperactive cells may undergo rapid membrane repair events that ensure viability. Indeed, pyroptotic events increase in cells that are defective for membrane repair mediated by the endosomal sorting complex required for transport machinery41.

Individual lipid moieties such as PGPC and POVPC, which constitute less than 10% of the total lipids present in the parental oxPAPC mixture21, induce NLRP3 inflammasome activation and the release of IL-1β from DCs and macrophages24. However, while the oxPAPC mixture induces a state of hyperactivation in DCs generated using granulocyte–macrophage colony-stimulating factor (GM-CSF), oxPAPCs were poor inducers of IL-1β secretion from the type 1 conventional DC (cDC1) subset or cDC2 subset of DCs34. In addition, oxPAPCs were capable of eliciting these responses only from DCs, not macrophages. Conversely, PGPC was able to induce inflammasome-dependent IL-1β secretion from living cDC1s, cDC2s and macrophages34. All these oxPAPC components engage CD14 and promote inflammasome-mediated IL-1β release from living cells (Fig. 2). Much work remains to be done to define the molecular events that dictate the specific cell fate commitments induced by oxPAPCs or the component lipids. Additional activities of oxPAPC components have been identified, which are described in the following sections.

Fig. 2: Mechanism of myeloid cell hyperactivation by oxidized phosphocholines.
figure 2

Lipopolysaccharide (LPS) is captured by surface CD14, which delivers this lipid to membrane-associated MD2 and Toll-like receptor 4 (TLR4). CD14 then transports LPS and TLR4 into the cell. TLR4 activation unleashes signalling pathways that stimulate an inflammatory response, resulting in the upregulation of many genes, including IL1B and NLRP3. This signal is recognized as a priming signal. Oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine derivatives (oxPAPCs) are also captured by CD14 and transported into the cell. Somehow oxPAPCs leave the endosomes and bind to caspase 11. This interaction leads to the oligomerization of an NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome that results in a hyperactive state, in which caspase 1 cleaves pro-IL-1β into its mature form and gasdermin D (GSDMD) into its active form. Hyperactive dendritic cells (DCs) induce IL-1β release without the commitment to pyroptosis. As depicted in the cell at the top of the figure, oxPAPC binding to CD14 prevents subsequent interactions with LPS.

Impact of oxPAPCs on DC migratory activity

Independently of their inflammasome-stimulatory activities, oxPAPCs promote the robust migratory capacity of TLR-activated DCs. Therefore, the hyperactivating stimuli LPS plus oxPAPCs (or PGPC) exceeded other activation stimuli (for example, LPS alone) in their ability to stimulate DC migration to adjacent draining lymph nodes34. RNA sequencing of the cDC1 and cDC2 subsets revealed that hyperactive DCs (primed with LPS and then stimulated with PGPC) upregulated the expression of several gene clusters involved in DC migration and chemotaxis34. Notably, DCs that were stimulated with LPS plus oxPAPCs or PGPC induced the upregulation of CC-chemokine receptor 7 (CCR7). Accordingly, LPS plus oxPL treatment of DCs enhanced their migratory activities to the draining lymph nodes after adoptive transfer into the skin34. The ability of oxPAPCs or their components to stimulate DC migration was independent of inflammasome activities, as no defects in DC migration were observed when studies were performed with cells lacking the inflammasome components NLRP3 or caspases 1 and 11. Although these findings expand the scope of immunological activities mediated by oxPAPCs, the mechanism by which oxPAPCs or PGPC modulates DC motility is undefined.

oxPAPC-mediated mitochondrial reprogramming in macrophages

Within macrophages, oxPAPCs stimulate metabolic reprogramming, termed ‘hypermetabolism’42. This metabolic state translates tissue oxidation status into heightened inflammatory gene expression. While macrophages activated by LPS downregulate their oxidative phosphorylation activities and rely on glycolysis for energy production, macrophages exposed to LPS and oxPAPCs used both oxidative phosphorylation and glycolysis. Under these conditions, the Krebs cycle is fed with glutamine, and pro-IL-1β production is enhanced by the increased activity of the transcription factor hypoxia-inducible factor 1α (HIF1α). This process is mediated by the accumulation of the metabolite oxaloacetate in the cytoplasm42.

The significance of the hypermetabolic state induced by oxPAPCs was revealed in atherosclerosis models, such as Ldlr−/− or Apoe−/− mice. When these mice were fed a high-fat diet, which drives oxPAPC accumulation in oxidized low-density lipoproteins, hypermetabolic phagocytes were identified in the blood. Interestingly, drugs that interfered with oxPAPC-driven metabolic changes reduced atherosclerotic plaque formation and protected mice against atherosclerosis development. It is speculated that this metabolic rewiring of macrophages increases mitochondrial fitness, which may prolong the lifespan of macrophages. In the context of infection, this hypermetabolic state may enhance host defence, but the same mechanism may underpin symptoms associated with heart disease and potentially other chronic inflammatory diseases.

Pure lipids contained within the oxPAPC mixture elicited distinct contributions to metabolic hyperinflammation. Whereas POVPC and PGPC drove inflammasome activation in macrophages, 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-sn-glycero-3-phosphocholine uniquely induced the hypermetabolic activities described above42. In another study, macrophages that were exposed to oxPAPCs acquired a unique redox-regulatory phenotype (referred to as Mox cells). Mox macrophages induce glutathione synthesis and depend on glucose to fuel cellular activities. This unusual macrophage phenotype was observed in atherosclerotic plaques of Ldlr−/− mice. Additional details about the metabolic activities of oxPLs in phagocytes are described in a recent review43.

Impact of oxPAPC on immune responses

oxPAPC-induced acute inflammatory responses

In the absence of PAMPs, oxPAPCs are weak inducers of cytokine production by myeloid cells24. In contrast to LPS, oxPAPCs did not induce TLR4 dimerization and endocytosis, myddosome formation or the expression of proinflammatory cytokines in macrophages21. However, in the context of animals, in which exposures to microbial products are difficult to control, oxPAPCs exhibit proinflammatory responses via TLR4 (refs14,43). Upon lung injury, oxPAPCs promoted IL-6 secretion from alveolar macrophages, and played a critical role in lung disease pathogenesis via a TLR4–TICAM pathway. Neutralization of oxPAPCs by the antibody E06 attenuated IL-6 production in the bronchoalveolar fluid. Furthermore, Shirey et al. described strong inhibition of oxPAPC-induced IL-6 production after treatment with the TLR4 antagonist eritoran43. Thus, in airways, oxPAPCs are potent stimulators of inflammation.

In contrast to the activities of oxPAPCs in the lung, studies of the peritoneal cavity revealed that oxPAPCs prevented TLR4 signalling21 and were described as LPS antagonists44,45. These anti-inflammatory activities of oxPAPCs in the peritoneum can be reproduced in vitro, where oxPAPC-treated phagocytes that were subsequently exposed to LPS exhibited defects in TLR4 dimerization and signalling. As a consequence, oxPAPC pretreatment inhibited LPS-inducible expression of interferon-stimulated genes and secretion of proinflammatory cytokines21. In addition, several studies indicated that pretreatment of DCs or macrophages with oxPAPCs blocks nuclear factor-κB responses to subsequent LPS treatments46,47,48,49. Mechanistic studies revealed that this inhibition of TLR signalling occurred by competitive interaction of LPS or oxPAPCs with CD14 (ref.21). Indeed, oxPAPCs and LPS interact with CD14 using the identical amino acids, thus providing a biochemical explanation for their competitive activities21. These mechanistic findings likely explain why co-injection of oxPAPCs and LPS into mice protected mice from lethal sepsis46, as under these conditions, both of these lipids compete with one another for CD14.

Recent studies identified PECPC as the most potent anti-inflammatory oxPAPC component50. Additionally, a small synthetic analogue of PGPC named ‘VB-201’, in which the ester bonds at sn-1 and sn-2 of the glycerol backbone are replaced with ether bonds to enhance the molecule’s stability against enzymatic degradation in vivo, was also shown to bind to CD14. VB-201 inhibits TLR2 and TLR4 in human and mouse monocytes and monocyte-derived DCs51. In addition, VB-201 administered orally ameliorated the severity of experimental autoimmune encephalomyelitis51, and inhibited liver inflammation in a mouse model of non-alcoholic steatohepatosis52.

These data highlight circumstances in which oxPAPCs are acutely inflammatory or immunosuppressive. These seemingly disparate observations may be explained by the mechanistic studies that have been performed. The proinflammatory activities of oxPAPCs in the lung may be explained by the presence of TLR4 ligands at this mucosal surface, which synergize with oxPAPCs to drive inflammation. By contrast, the anti-inflammatory activities in the peritoneal cavity may be explained by the lack of resident TLR ligands to synergize with oxPAPCs. In this latter context, oxPAPC injection leads to reduced inflammatory responses to subsequent bacterial infections, perhaps because oxPAPC pre-injection saturates cellular pools of CD14 that would normally be stimulated by bacterial products. Support for this idea was provided by recent data demonstrating that pretreatment of the peritoneal cavity of mice with LPS enabled oxPAPCs to induce inflammation21. By contrast, oxPAPC injection into the peritoneum in the absence of LPS priming elicits no inflammatory response21.

The immunomodulatory activities of oxPAPCs described above are associated with rapid innate immune responses that occur within minutes to hours of cellular exposure. In the next section we describe recent assessments of the impact of oxPAPCs on the long-term adaptive immune responses in the context of cancer.

oxPAPC-mediated control of adaptive immunity

oxPAPCs can regulate adaptive immunity by acting on antigen-presenting cells. Hyperactive DCs stimulated with LPS and PGPC induced antitumour CD8+ T cell responses in mice that resulted from inflammasome activities within living DCs, and their hypermigratory ability that enables tumour antigens to reach lymphoid tissues (Fig. 3). These migratory DCs continuously secrete IL-1β to prime de novo T cells and activate memory T cells34,53. Consequently, LPS plus PGPC was a strong adjuvant to complex tumour antigens (for example, whole tumour lysates) during prophylactic or therapeutic immunizations against a range of murine tumours. Recent studies in humans revealed the need for multiple neoantigens (up to 20 peptides) for effective generation of personalized cancer therapies54,55,56. The ability of oxPLs to adjuvant whole tumour lysates may bypass the challenge of neoantigen identification and enable immunotherapies to be developed that are agnostic to the identity of tumour antigens34. It is likely that hyperactivating stimuli uniquely elicit the generation of a wide diversity of antigen-specific T cells, perhaps due to their abundance in the draining lymph node. Indeed, oxPAPC-containing or PGPC-containing adjuvants potentiated the generation of antigen-specific T cell responses and increased the kinetics of memory and effector T cell generation34.

Fig. 3: Hyperactive DCs control antitumour T cell immunity.
figure 3

Upon pathogen encounter, immature dendritic cells (DCs) circulating in the peripheral tissue recognize pathogen-associated molecular patterns (PAMPs) via Toll like-receptors (TLRs) and shift their activities from a naive state to an active state. In the presence of tissue damage, CD14 captures 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine (PGPC) and delivers the lipids to caspase 11 to induce NLR family pyrin domain-containing protein 3 (NLRP3) activation. These DCs achieve a long-lived state of hyperactivation, leading to IL-1β release from living DCs. Hyperactive DCs upregulate CC-chemokine receptor 7 (CCR7) expression and retain the ability for antigen uptake and processing of antigenic peptide on MHC class I. Hyperactive DCs carrying antigens then migrate to the draining lymph node via CCR7, where they activate CD8+ T cells. IL-1β secreted by hyperactive DCs signal via IL-1 receptor (IL-1R) to stimulate T cell effector function. IFNγ, interferon-γ; TCR, T cell receptor.

In considering the underlying logic to the benefit of hyperactivating stimuli on antitumour immunity, we return to the central thesis we have proposed. We propose that the conditions of DC hyperactivation — where cells are exposed to generic indicators of microorganisms (TLR ligands) and tissue injury (oxPAPCs) — mimic the microenvironment of a virulent infection. Under these conditions, DCs receive multiple signals necessary to maximally enhance their migratory activities, metabolic activities and T cell stimulatory activities. The result of this enhancement is a superior adaptive immune response that enhances antitumour immunity. While the genesis of our logic derives from consideration of infectious encounters, these ideas have yet to be tested in this context. Of note, oxPLs, including oxidized low-density lipoprotein, are highly enriched in the tumour microenvironment. It was shown that oxidized low-density lipoprotein induces lipid peroxidation that suppresses CD8+ T cell effector functions in the tumour in a CD36-dependent manner57. These data provide the mandate to explore the links between lipid oxidation and cancer immunotherapy.

Unrecognized sources of oxPAPCs may underlie diverse immunotherapies

Although the role of hyperactive DCs in adaptive immunity needs further exploration, it is worth considering whether the protective activities of current therapies may depend on previously unrecognized oxPAPC sources that drive cell hyperactivation. For example, the chemotherapeutic chemicals oxaliplatin and anthracycline stimulate IL‐1β production via NLRP3 inflammasomes, leading to tumour-specific CD8+ T cell responses57. Oxaliplatin is known to stimulate ROS, whose activities may generate PGPC and other oxPAPCs within the tumour. These factors would act with any coexisting PAMPs to hyperactivate DCs and prime antitumour T cell responses. Consistent with this idea is evidence that patients with breast cancer bearing mutations in the inflammasome regulator P2X7R can develop rapid metastatic disease57,58. Total body irradiation should also induce oxPAPC formation, via the generation of ROS that occurs in these contexts. The impact of radiation-induced (or chemotherapy-induced) oxPAPC production on tumour immunity remains speculative. If these ideas are proven in humans, it is possible that vaccines could be engineered to specifically introduce oxPL moieties as adjuvants to promote more effective antigen-specific T cell responses.

Conclusions and perspectives

We suggest that heterogeneous oxPAPC mixtures or pure oxPAPC components cannot be classified as intrinsically proinflammatory or anti-inflammatory molecules. It is likely that the pleiotropic effects of oxPAPCs work in concert in vivo. In this regard, our knowledge is currently limited, as little is known about the identity and function of specific oxPAPC compounds. Further research is required to better understand the biological role of oxPAPCs during infectious diseases and other threats to the host. Recent evidence indicates that PGPC and POVPC can prevent vesicular stomatitis virus entry, thereby limiting viral replication59. Although the mechanism by which oxPAPCs inhibit viral entry is undetermined, these data provide the mandate to explore the interplay of pathogens and oxPLs, which may open new avenues for novel therapeutic targets.

Furthermore, a better understanding of how endogenous oxPLs impact phagocyte function is crucial for uncovering the impact of oxPLs on homeostasis and pathogenesis. POVPC abundance is increased in the lungs of aged mice, and these levels are further augmented upon inflammatory stimulation60. In addition, the clearance of oxPLs from lungs was delayed in aged mice60, and correlated with severe lung injury and delayed resolution. In this regard, several questions remain unexplored. How do these oxPLs regulate phagocyte function in the ageing host? Can these lipids regulate the inflammaging process? This knowledge could support the development of effective vaccination strategies designed for elderly patients.

oxPLs enzymatically derived from innate immune cells were shown to promote coagulation factor function which restored thrombin generation. Therefore, it was proposed that bioactive oxPLs may be a target in bleeding and vascular inflammation disorders61,62. Interestingly, pyroptotic macrophages were shown to release tissue factor (an essential initiator of coagulation cascades) following inflammasome activation, which triggered blood clotting63. Whether oxPLs can regulate blood clotting via inflammasome activation is a possibility.

Finally, oxPLs are not the only stimuli that can induce a state of DC hyperactivation. Other hyperactivating stimuli besides oxPLs have been reported64, including bacterial peptidoglycan65, Staphylococcus aureus ΔoatA mutants66 and the TLR agonist R848 plus muramyl dipeptide67. The latter induces human cDC2 hyperactivation that enhances T helper 1 and T helper 17 cell responses. Whether hyperactivating stimuli could be generally classified as boosters of adaptive T cell immunity or context-dependent regulators of immunity requires further investigation.

References

  1. Medzhitov, R. & Janeway, C. A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91, 295–298 (1997).

    CAS  PubMed  Article  Google Scholar 

  2. Janeway, C. A. & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197–216 (2002).

    CAS  PubMed  Article  Google Scholar 

  3. Pasare, C. & Medzhitov, R. Control of B-cell responses by Toll-like receptors. Nature 438, 364–368 (2005).

    CAS  PubMed  Article  Google Scholar 

  4. Iwasaki, A. & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16, 343–353 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. Fitzgerald, K. A. & Kagan, J. C. Toll-like receptors and the control of immunity. Cell 180, 1044–1066 (2020).

    CAS  PubMed  Article  Google Scholar 

  6. Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat. Immunol. 11, 373–384 (2010).

    CAS  PubMed  Article  Google Scholar 

  7. Vance, R. E. Immunology taught by bacteria. J. Clin. Immunol. 30, 507–511 (2010).

    PubMed  PubMed Central  Article  Google Scholar 

  8. Miao, E. A. & Warren, S. E. Innate immune detection of bacterial virulence factors via the NLRC4 inflammasome. J. Clin. Immunol. 30, 502–506 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. Vance, R. E., Isberg, R. R. & Portnoy, D. A. Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system. Cell Host Microbe 6, 10–21 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. Lamkanfi, M. & Dixit, V. M. Mechanisms and functions of inflammasomes. Cell 157, 1013–1022 (2014).

    CAS  PubMed  Article  Google Scholar 

  11. Franchi, L., Muñoz-Planillo, R. & Núñez, G. Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 13, 325–332 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. Evavold, C. L. & Kagan, J. C. Inflammasomes: threat-assessment organelles of the innate immune system. Immunity 51, 609–624 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. Kieser, K. J. & Kagan, J. C. Multi-receptor detection of individual bacterial products by the innate immune system. Nat. Rev. Immunol. 17, 376–390 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. Imai, Y. et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133, 235–249 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. Berliner, J. A. & Watson, A. D. A role for oxidized phospholipids in atherosclerosis. N. Engl. J. Med. 353, 9–11 (2005).

    CAS  PubMed  Article  Google Scholar 

  16. Leitinger, N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr. Op. Lipidol. 14, 421–430 (2003).

    CAS  Article  Google Scholar 

  17. Bochkov, V. N. et al. Generation and biological activities of oxidized phospholipids. Antioxid. Redox Signal. 12, 1009–1059 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. Febbraio, M., Hajjar, D. P. & Silverstein, R. L. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108, 785–791 (2001).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. Kar, N. S., Ashraf, M. Z., Valiyaveettil, M. & Podrez, E. A. Mapping and characterization of the binding site for specific oxidized phospholipids and oxidized low density lipoprotein of scavenger receptor CD36. J. Biol. Chem. 283, 8765–8771 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  20. Boullier, A. et al. Phosphocholine as a pattern recognition ligand for CD36. J. Lipid Res. 46, 969–976 (2005).

    CAS  PubMed  Article  Google Scholar 

  21. Zanoni, I., Tan, Y., di Gioia, M., Springstead, J. R. & Kagan, J. C. By capturing inflammatory lipids released from dying cells, the receptor CD14 induces inflammasome-dependent phagocyte hyperactivation. Immunity 47, 697–709.e3 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. Tan, Y., Zanoni, I., Cullen, T. W., Goodman, A. L. & Kagan, J. C. Mechanisms of Toll-like receptor 4 endocytosis reveal a common immune-evasion strategy used by pathogenic and commensal bacteria. Immunity 43, 909–922 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. Shirey, K. A. et al. The TLR4 antagonist eritoran protects mice from lethal influenza infection. Nature 497, 498–502 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. Zanoni, I. et al. An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells. Science 352, 1232–1236 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. Shi, J. et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187–192 (2014).

    CAS  PubMed  Article  Google Scholar 

  26. Kayagaki, N. et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341, 1246–1249 (2013).

    CAS  PubMed  Article  Google Scholar 

  27. Dingjan, I. et al. Lipid peroxidation causes endosomal antigen release for cross-presentation. Sci. Rep. 6, 22064 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. Ashraf, M. Z. & Srivastava, S. In Lipoproteins: Role in Health and Diseases (ed. Kostner, G.) Ch. 17 (IntechOpen, 2012).

  29. Matt, U., Sharif, O., Martins, R. & Knapp, S. Accumulating evidence for a role of oxidized phospholipids in infectious diseases. Cell. Mol. Life Sci. 72, 1059–1071 (2015).

    CAS  PubMed  Article  Google Scholar 

  30. Bochkov, V. et al. Pleiotropic effects of oxidized phospholipids. Free Radic. Biol. Med. 111, 6–24 (2017).

    CAS  PubMed  Article  Google Scholar 

  31. Knapp, S., Matt, U., Leitinger, N. & van der Poll, T. Oxidized phospholipids inhibit phagocytosis and impair outcome in gram-negative sepsis in vivo. J. Immunol. 178, 993–1001 (2007).

    CAS  PubMed  Article  Google Scholar 

  32. Thimmulappa, R. K. et al. Oxidized phospholipids impair pulmonary antibacterial defenses: evidence in mice exposed to cigarette smoke. Biochem. Biophys. Res. Commun. 426, 253–259 (2012).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. Greenberg, M. E. et al. Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J. Exp. Med. 203, 2613–2625 (2006).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. Zhivaki, D. et al. Inflammasomes within hyperactive murine dendritic cells stimulate long-lived T cell-mediated anti-tumor immunity. Cell Rep. 33, 108381 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  35. Garlanda, C., Dinarello, C. A. & Mantovani, A. The interleukin-1 family: back to the future. Immunity 39, 1003–1018 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10, 417–426 (2002).

    CAS  PubMed  Article  Google Scholar 

  37. Ding, J. et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111–116 (2016).

    CAS  PubMed  Article  Google Scholar 

  38. Heilig, R. et al. The gasdermin-D pore acts as a conduit for IL-1β secretion in mice. Eur. J. Immunol. 48, 584–592 (2018).

    CAS  PubMed  Article  Google Scholar 

  39. Evavold, C. L. et al. The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages. Immunity 48, 35–44 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  40. Xia, S. et al. Gasdermin D pore structure reveals preferential release of mature interleukin-1. Nature 593, 607–611 (2021).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. Rühl, S. et al. ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. Science 362, 956–960 (2018).

    PubMed  Article  CAS  Google Scholar 

  42. di Gioia, M. et al. Endogenous oxidized phospholipids reprogram cellular metabolism and boost hyperinflammation. Nat. Immunol. 21, 42–53 (2020).

    PubMed  Article  CAS  Google Scholar 

  43. Di Gioia, M. & Zanoni, I. Dooming phagocyte responses: inflammatory effects of endogenous oxidized phospholipids. Front. Endocrinol. https://doi.org/10.3389/fendo.2021.626842 (2021).

    Article  Google Scholar 

  44. Serbulea, V. et al. Macrophages sensing oxidized DAMPs reprogram their metabolism to support redox homeostasis and inflammation through a TLR2-Syk-ceramide dependent mechanism. Mol. Metab. 7, 23–34 (2018).

    CAS  PubMed  Article  Google Scholar 

  45. Oskolkova, O. V. et al. Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. J. Immunol. 185, 7706–7712 (2010).

    CAS  PubMed  Article  Google Scholar 

  46. Bochkov, V. N. et al. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 419, 77–81 (2002).

    CAS  PubMed  Article  Google Scholar 

  47. Walton, K. A. et al. Specific phospholipid oxidation products inhibit ligand activation of Toll-like receptors 4 and 2. Arterioscler. Thromb. Vasc. Biol. 23, 1197–1203 (2003).

    CAS  PubMed  Article  Google Scholar 

  48. Erridge, C., Kennedy, S., Spickett, C. M. & Webb, D. J. Oxidized phospholipid inhibition of Toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. J. Biol. Chem. 283, 24748–24759 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. Chu, L. H. et al. The oxidized phospholipid oxPAPC protects from septic shock by targeting the non-canonical inflammasome in macrophages. Nat. Commun. 9, 996 (2018).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  50. Bretscher, P. et al. Phospholipid oxidation generates potent anti-inflammatory lipid mediators that mimic structurally related pro-resolving eicosanoids by activating Nrf2. EMBO Mol. Med. 7, 593–607 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. Mendel, I. et al. A lecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease. J. Neuroimmunol. 226, 126–135 (2010).

    CAS  PubMed  Article  Google Scholar 

  52. Mendel, I., Yacov, N., Shoham, A., Ishai, E. & Breitbart, E. Treatment with oxidized phospholipids directly inhibits nonalcoholic steatohepatitis and liver fibrosis without affecting steatosis. Dig. Dis. Sci. 61, 2545–2553 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. Jain, A., Song, R., Wakeland, E. K. & Pasare, C. T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells. Nat. Commun. 9, 1–13 (2018).

    Article  CAS  Google Scholar 

  54. Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081–1091 (2012).

    CAS  PubMed  Article  Google Scholar 

  56. Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515–525 (2021).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1Β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009).

    CAS  PubMed  Article  Google Scholar 

  58. Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691–1701 (2005).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. Ernandes, M. J. & Kagan, J. C. Interferon-independent restriction of RNA virus entry and replication by a class of damage-associated molecular patterns. mBio 12, e00584–21 (2021).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  60. Ke, Y. et al. Elevated truncated oxidized phospholipids as a factor exacerbating ALI in the aging lungs. FASEB J. 33, 3887–3900 (2019).

    CAS  PubMed  Article  Google Scholar 

  61. Slatter, D. A. et al. Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies. JCI Insight 3, e98459 (2018).

    PubMed Central  Article  Google Scholar 

  62. O’Donnell, V. B., Aldrovandi, N., Murphy, R. C. & Krönke, G. Enzymatically oxidized phospholipids assume center stage as essential regulators of innate immunity and cell death. Sci. Signal. 12, eaau2293 (2019).

    PubMed  Article  CAS  Google Scholar 

  63. Wu, C. et al. Inflammasome activation triggers blood clotting and host death through pyroptosis. Immunity 50, 1401 (2019).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. Zhivaki, D. & Kagan, J. C. NLRP3 inflammasomes that induce antitumor immunity. Trends Immunol. 42, 575–589 (2021).

    CAS  PubMed  Article  Google Scholar 

  65. Wolf, A. J. et al. Hexokinase is an innate immune receptor for the detection of bacterial peptidoglycan. Cell 166, 624–636 (2016).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. Shimada, T. et al. Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1β secretion. Cell Host Microbe 7, 38–49 (2010).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. Hatscher, L. et al. Select hyperactivating NLRP3 ligands enhance the TH1- and TH17-inducing potential of human type 2 conventional dendritic cells. Sci. Signal. 14, eabe1757 (2021).

    CAS  PubMed  Article  Google Scholar 

  68. Brubaker, S. W., Bonham, K. S., Zanoni, I. & Kagan, J. C. Innate immune pattern recognition: a cell biological perspective. Annu. Rev. Immunol. 33, 257–290 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. Matzinger, P. The danger model: a renewed sense of self. Science 296, 301–305 (2002).

    CAS  PubMed  Article  Google Scholar 

  70. Kagan, J. C. Lipopolysaccharide detection across the kingdoms of life. Trends Immunol. 38, 696–704 (2017).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  71. Gauthier, A. E. et al. Deep-sea microbes as tools to refine the rules of innate immune pattern recognition. Sci. Immunol. 6, eabe0531 (2021).

    PubMed  PubMed Central  Article  Google Scholar 

  72. Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81, 1–5 (2007).

    CAS  PubMed  Article  Google Scholar 

  73. Lorent, J. H. et al. Plasma membranes are asymmetric in lipid unsaturation, packing and protein shape. Nat. Chem. Biol. 16, 644–652 (2020).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  74. Bernhard, W. et al. Phosphatidylcholine molecular species in lung surfactant composition in relation to respiratory rate and lung development. Am. J. Resp. Cell Mol. Biol. 25, 725–731 (2001).

    CAS  Article  Google Scholar 

  75. Bergmark, C. et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49, 2230–2239 (2008).

    CAS  PubMed  Article  Google Scholar 

  76. O’Donnell, V. B., Rossjohn, J. & Wakelam, M. J. O. Phospholipid signaling in innate immune cells. J. Clin. Invest. 128, 2670–2679 (2018).

    PubMed  PubMed Central  Article  Google Scholar 

  77. Hajeyah, A. A., Griffiths, W. J., Wang, Y., Finch, A. J. & O’Donnell, V. B. The biosynthesis of enzymatically oxidized lipids. Front. Endocrinol. https://doi.org/10.3389/fendo.2020.591819 (2020).

    Article  Google Scholar 

  78. Huber, J. et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler. Thromb. Vasc. Biol. 22, 101–107 (2002).

    CAS  PubMed  Article  Google Scholar 

  79. Tsiantoulas, D. et al. Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. J. Lipid Res. 56, 440–448 (2015).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  80. Watson, A. D. et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272, 13597–13607 (1997).

    CAS  PubMed  Article  Google Scholar 

  81. Qin, J., Goswami, R., Balabanov, R. & Dawson, G. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J. Neurosci. Res. 85, 977–984 (2007).

    CAS  PubMed  Article  Google Scholar 

  82. Kanter, J. L. et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12, 138–143 (2006).

    CAS  PubMed  Article  Google Scholar 

  83. Sun, X. et al. Neutralization of oxidized phospholipids ameliorates non-alcoholic steatohepatitis. Cell Metab. 31, 189–206.e8 (2020).

    CAS  PubMed  Article  Google Scholar 

  84. Bochkov, V. N. et al. Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ. Res. 99, 900–908 (2006).

    CAS  PubMed  Article  Google Scholar 

  85. Bochkov, V. et al. Novel immune assay for quantification of plasma protective capacity against oxidized phospholipids. Biomark. Med. 10, 797–810 (2016).

    CAS  PubMed  Article  Google Scholar 

  86. Gruber, F. et al. Photooxidation generates biologically active phospholipids that induce heme oxygenase-1 in skin cells. J. Biol. Chem. 282, 16934–16941 (2007).

    CAS  PubMed  Article  Google Scholar 

  87. Que, X. et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolemic mice. Nature 558, 301 (2018).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  88. Ståhle, M. et al. Therapeutic antibody against phosphorylcholine preserves coronary function and attenuates vascular 18F-FDG uptake in atherosclerotic mice. JACC Basic Transl. Sci. 5, 360–373 (2020).

    PubMed  PubMed Central  Article  Google Scholar 

  89. Inaba, K. et al. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J. Exp. Med. 191, 927–936 (2000).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  90. Mellman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255–258 (2001).

    CAS  PubMed  Article  Google Scholar 

  91. Joffre, O., Nolte, M. A., Spörri, R. & Reis e Sousa, C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 227, 234–247 (2009).

    CAS  PubMed  Article  Google Scholar 

  92. Sallusto, F. & Lanzavecchia, A. The instructive role of dendritic cells on T-cell responses. Arthr. Res. 4, S127–S132 (2002).

    Article  Google Scholar 

  93. Sabado, R. L., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res. 27, 74–95 (2017).

    CAS  PubMed  Article  Google Scholar 

  94. Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24 (2020).

    CAS  PubMed  Article  Google Scholar 

  95. Draube, A. et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS ONE 6, e18801 (2011).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  96. Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168–182 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  97. Ben-Sasson, S. Z. et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc. Natl Acad. Sci. USA 106, 7119–7124 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  98. Ben-Sasson, S. Z. et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J. Exp. Med. 210, 491–502 (2013).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  99. Lu, A. et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 156, 1193–1206 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  100. Kagan, J. C., Magupalli, V. G. & Wu, H. SMOCs: supramolecular organizing centres that control innate immunity. Nat. Rev. Immunol. 14, 821–826 (2014).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  101. Mempel, T. R., Henrickson, S. E. & von Andrian, U. H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427, 154–159 (2004).

    CAS  PubMed  Article  Google Scholar 

  102. Eisenbarth, S. C. et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122–1126 (2008).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  103. Kool, M. et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181, 3755–3759 (2008).

    CAS  PubMed  Article  Google Scholar 

  104. Marrack, P., McKee, A. S. & Munks, M. W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9, 287–293 (2009).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references

Acknowledgements

The authors thank the members of the Kagan laboratory for helpful discussions. This work was supported by US National Institutes of Health grants AI133524, AI093589, AI116550 and P30DK34854 (J.C.K.). D.Z. was funded by the Charles King Trust Fellowship.

Author information

Authors and Affiliations

Authors

Contributions

The authors contributed equally to all aspects of the article.

Corresponding author

Correspondence to Jonathan C. Kagan.

Ethics declarations

Competing interests

J.C.K. holds equity in and consults for IFM Therapeutics and Corner Therapeutics. D.Z. holds equity in and consults for Corner Therapeutics. None of these relationships influenced the manuscript.

Additional information

Peer review information

Nature Reviews Immunology thanks V. Bochkov and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhivaki, D., Kagan, J.C. Innate immune detection of lipid oxidation as a threat assessment strategy. Nat Rev Immunol 22, 322–330 (2022). https://doi.org/10.1038/s41577-021-00618-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41577-021-00618-8

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing